Global Amyotrophic Lateral Sclerosis (ALS) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amyotrophic Lateral Sclerosis (ALS) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic Lateral Sclerosis (ALS) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amyotrophic Lateral Sclerosis (ALS) market is projected to reach US$ 379.1 million in 2029, increasing from US$ 300 million in 2022, with the CAGR of 2.6% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amyotrophic Lateral Sclerosis (ALS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Hospital
Drugs Store
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Amyotrophic Lateral Sclerosis (ALS) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amyotrophic Lateral Sclerosis (ALS), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amyotrophic Lateral Sclerosis (ALS) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Amyotrophic Lateral Sclerosis (ALS) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amyotrophic Lateral Sclerosis (ALS) introduction, etc. Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Amyotrophic Lateral Sclerosis (ALS) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic Lateral Sclerosis (ALS) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amyotrophic Lateral Sclerosis (ALS) market is projected to reach US$ 379.1 million in 2029, increasing from US$ 300 million in 2022, with the CAGR of 2.6% during the period of 2024 to 2029. Demand from Hospital and Drugs Store are the major drivers for the industry.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amyotrophic Lateral Sclerosis (ALS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Amyotrophic Lateral Sclerosis (ALS) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amyotrophic Lateral Sclerosis (ALS), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amyotrophic Lateral Sclerosis (ALS) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Amyotrophic Lateral Sclerosis (ALS) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amyotrophic Lateral Sclerosis (ALS) introduction, etc. Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Amyotrophic Lateral Sclerosis (ALS) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices